HTD 4010

Drug Profile

HTD 4010

Alternative Names: HTD4010

Latest Information Update: 08 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HighTide Biopharma
  • Class Antihyperglycaemics; Cytokines; Peptide fragments
  • Mechanism of Action Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2016 HighTide BioPharma plans a phase II trial for Type-2 diabetes
  • 01 Mar 2016 HighTide Biopharma completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in Australia (Parenteral) (NCT02538848)
  • 31 Aug 2015 Preclinical trials in Type-2 diabetes mellitus in Australia (Parenteral) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top